OBJECTIVE: To evaluate carbonic anhydrase IX (CAIX) expression as an independent prognostic marker for clear cell renal cell carcinoma (ccRCC). With recent smaller studies showing conflicting results, we aimed to update our initial analysis in 2007 with an additional 5-year follow-up. PATIENTS AND METHODS: We provided long-term follow-up of the same cohort used in our 2007 study (730 patients with unilateral, sporadic ccRCC treated surgically between 1990 and 1999). Associations of CAIX expression with RCC death and distant metastases were evaluated using Cox proportional hazards regression models. RESULTS: CAIX was expressed in 708 (97.0%) of the specimens; 163 tumours (22.3%) had low (≤85%) expression and 567 (77.7%) high (>85%) expression. There were 483 deaths and 265 RCC-specific deaths. The median follow-up for the 247 patients still under observation was 13.8 years. Univariately, low CAIX expression was associated with an increased risk of RCC death vs high expression (hazard ratio 1.62; P < 0.001). Low CAIX expression was not statistically significantly associated with RCC death or distant metastases after adjusting for nuclear grade or coagulative tumour necrosis. CONCLUSION: After additional long-term follow-up of our large cohort, our results continue to suggest that CAIX is not an independent prognostic marker for ccRCC.
OBJECTIVE: To evaluate carbonic anhydrase IX (CAIX) expression as an independent prognostic marker for clear cell renal cell carcinoma (ccRCC). With recent smaller studies showing conflicting results, we aimed to update our initial analysis in 2007 with an additional 5-year follow-up. PATIENTS AND METHODS: We provided long-term follow-up of the same cohort used in our 2007 study (730 patients with unilateral, sporadic ccRCC treated surgically between 1990 and 1999). Associations of CAIX expression with RCC death and distant metastases were evaluated using Cox proportional hazards regression models. RESULTS:CAIX was expressed in 708 (97.0%) of the specimens; 163 tumours (22.3%) had low (≤85%) expression and 567 (77.7%) high (>85%) expression. There were 483 deaths and 265 RCC-specific deaths. The median follow-up for the 247 patients still under observation was 13.8 years. Univariately, low CAIX expression was associated with an increased risk of RCC death vs high expression (hazard ratio 1.62; P < 0.001). Low CAIX expression was not statistically significantly associated with RCC death or distant metastases after adjusting for nuclear grade or coagulative tumour necrosis. CONCLUSION: After additional long-term follow-up of our large cohort, our results continue to suggest that CAIX is not an independent prognostic marker for ccRCC.
Authors: Manal Gabril; Hala Girgis; Andreas Scorilas; Fabio Rotondo; Samantha Wala; Georg A Bjarnason; Qiang Ding; Andrew Evans; Eriny Tawedrous; Maria Pasic; Antonio Finelli; Sahar Al-Haddad; George M Yousef Journal: Clin Exp Metastasis Date: 2016-01 Impact factor: 5.150
Authors: Jonathan M Weiss; W Gregory Alvord; Octavio A Quiñones; Jimmy K Stauffer; Robert H Wiltrout Journal: Hum Immunol Date: 2014-05-04 Impact factor: 2.850
Authors: Grant D Stewart; Fiach C O'Mahony; Alexander Laird; Sukaina Rashid; Sarah A Martin; Lel Eory; Alexander L R Lubbock; Jyoti Nanda; Marie O'Donnell; Alan Mackay; Peter Mullen; S Alan McNeill; Antony C P Riddick; Michael Aitchison; Daniel Berney; Axel Bex; Ian M Overton; David J Harrison; Thomas Powles Journal: Eur Urol Date: 2014-05-10 Impact factor: 20.096
Authors: Hala Girgis; Olena Masui; Nicole Ma White; Andreas Scorilas; Fabio Rotondo; Annetta Seivwright; Manal Gabril; Emily R Filter; Andrew Ha Girgis; Georg A Bjarnason; Michael As Jewett; Andrew Evans; Sahar Al-Haddad; Kw Michael Siu; George M Yousef Journal: Mol Cancer Date: 2014-05-05 Impact factor: 27.401